AURKA and medulloblastoma: Our preclinical investigations targeting Aurora-A kinase inhibition with MLN8237 in GTML/Trp53KI/KI mice, together with recent research describing CD532 (an Aurora-A inhibitor structurally distinct from MLN8237) (Gustafson et al., 2014), demonstrate proof-of-principle for indirect therapeutic targeting of MYCN in medulloblastoma and its advancement to the clinic.